[
  {
    "ts": null,
    "headline": "Reasons to Retain Avanos Medical Stock in Your Portfolio Now",
    "summary": "AVNS shows solid 3Q25 momentum from SNS and PMR growth, aided by M&A and cost cuts, even as tariffs and FX volatility linger.",
    "url": "https://finnhub.io/api/news?id=20818c7f151c06a005ca2532881c21c3ff37f0bd1d06995817b38c0ae4aec795",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769711520,
      "headline": "Reasons to Retain Avanos Medical Stock in Your Portfolio Now",
      "id": 138300124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "AVNS shows solid 3Q25 momentum from SNS and PMR growth, aided by M&A and cost cuts, even as tariffs and FX volatility linger.",
      "url": "https://finnhub.io/api/news?id=20818c7f151c06a005ca2532881c21c3ff37f0bd1d06995817b38c0ae4aec795"
    }
  },
  {
    "ts": null,
    "headline": "Organon Completes Divesture of JADA System to Laborie Medical",
    "summary": "OGN completes JADA System divestiture to Laborie for up to $465M, bolstering its balance sheet and backing debt reduction to fund women's health growth.",
    "url": "https://finnhub.io/api/news?id=6563bf9d1b436241bd6a59c26b66738d2bd8aaf387b023e3275b6342f43c3f67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769711280,
      "headline": "Organon Completes Divesture of JADA System to Laborie Medical",
      "id": 138300125,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "OGN completes JADA System divestiture to Laborie for up to $465M, bolstering its balance sheet and backing debt reduction to fund women's health growth.",
      "url": "https://finnhub.io/api/news?id=6563bf9d1b436241bd6a59c26b66738d2bd8aaf387b023e3275b6342f43c3f67"
    }
  },
  {
    "ts": null,
    "headline": "Reasons to Add AngioDynamics Stock to Your Portfolio for Now",
    "summary": "ANGO stock is buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer, and broad Med Tech growth supporting margins.",
    "url": "https://finnhub.io/api/news?id=b4f33f8d9cff6518084ac5084b3d7a16a84f2e18062ff9a2b1459b7fe4686448",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769708820,
      "headline": "Reasons to Add AngioDynamics Stock to Your Portfolio for Now",
      "id": 138298590,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "ANGO stock is buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer, and broad Med Tech growth supporting margins.",
      "url": "https://finnhub.io/api/news?id=b4f33f8d9cff6518084ac5084b3d7a16a84f2e18062ff9a2b1459b7fe4686448"
    }
  },
  {
    "ts": null,
    "headline": "CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up",
    "summary": "CNMD posts strong fourth-quarter 2025 results with EPS and revenue beat, driven by surgical growth and improved gross margin.",
    "url": "https://finnhub.io/api/news?id=e01810e48b5ec35d0ea7677247b08c939025b75ce860f07429494af1845ff169",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769707020,
      "headline": "CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up",
      "id": 138298591,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "CNMD posts strong fourth-quarter 2025 results with EPS and revenue beat, driven by surgical growth and improved gross margin.",
      "url": "https://finnhub.io/api/news?id=e01810e48b5ec35d0ea7677247b08c939025b75ce860f07429494af1845ff169"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher's Q4 Earnings & Revenues Top Estimates, Stock Climbs",
    "summary": "TMO beats Q4 EPS and revenue estimates, posts 7.1% sales growth, and sees shares rise after results despite margin pressure.",
    "url": "https://finnhub.io/api/news?id=dc7ed77bdc8f8d09f3abc57a19a26c4ed851697c790d48f7a56778827cc2286a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769694480,
      "headline": "Thermo Fisher's Q4 Earnings & Revenues Top Estimates, Stock Climbs",
      "id": 138297195,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "TMO beats Q4 EPS and revenue estimates, posts 7.1% sales growth, and sees shares rise after results despite margin pressure.",
      "url": "https://finnhub.io/api/news?id=dc7ed77bdc8f8d09f3abc57a19a26c4ed851697c790d48f7a56778827cc2286a"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why You Should Retain Glaukos Stock in Your Portfolio Now",
    "summary": "GKOS is positioned for growth as interventional glaucoma adoption expands, iDose and iStent synergies build, and scale drives operating leverage despite margin pressures.",
    "url": "https://finnhub.io/api/news?id=46391b08410867e5978a61329aab28e6d63df5ee19643b52f4f699ff9707840e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769693520,
      "headline": "Here's Why You Should Retain Glaukos Stock in Your Portfolio Now",
      "id": 138295712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "GKOS is positioned for growth as interventional glaucoma adoption expands, iDose and iStent synergies build, and scale drives operating leverage despite margin pressures.",
      "url": "https://finnhub.io/api/news?id=46391b08410867e5978a61329aab28e6d63df5ee19643b52f4f699ff9707840e"
    }
  },
  {
    "ts": null,
    "headline": "Artisan Global Opportunities Fund Q4 2025 Portfolio Update",
    "summary": "Among our top contributors in Q4 were Argenx, Lam Research and Insmed. Among our biggest detractors in Q4 were Oracle, Netflix and BAE Systems.",
    "url": "https://finnhub.io/api/news?id=789efafe0ea1abad3298dd0d892e3e120dcf79f6dc7fd9c021bfbd154cc0072e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769679540,
      "headline": "Artisan Global Opportunities Fund Q4 2025 Portfolio Update",
      "id": 138295158,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1340690121/image_1340690121.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Among our top contributors in Q4 were Argenx, Lam Research and Insmed. Among our biggest detractors in Q4 were Oracle, Netflix and BAE Systems.",
      "url": "https://finnhub.io/api/news?id=789efafe0ea1abad3298dd0d892e3e120dcf79f6dc7fd9c021bfbd154cc0072e"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Stock: Analyst Estimates & Ratings",
    "summary": "Though Boston Scientific has lagged behind the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=285864f3961467eef684b7d66dacfcedb3df7dfef1b8882cab8feb59a1218163",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769668692,
      "headline": "Boston Scientific Stock: Analyst Estimates & Ratings",
      "id": 138293188,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Though Boston Scientific has lagged behind the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=285864f3961467eef684b7d66dacfcedb3df7dfef1b8882cab8feb59a1218163"
    }
  },
  {
    "ts": null,
    "headline": "3 Market-Beating Stocks with Exciting Potential",
    "summary": "The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.",
    "url": "https://finnhub.io/api/news?id=540f450accc2af1eaa20ce6c1a6e15e6ca2e3ca034e2ca0f8dbec90ea4d425a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769661406,
      "headline": "3 Market-Beating Stocks with Exciting Potential",
      "id": 138298592,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.",
      "url": "https://finnhub.io/api/news?id=540f450accc2af1eaa20ce6c1a6e15e6ca2e3ca034e2ca0f8dbec90ea4d425a9"
    }
  }
]